Artiva stockholders approve 1.2M share increase to 2024 equity plan, re-elect director Baker

Artiva Biotherapeutics, Inc.

Amendment to 2024 Equity Incentive Plan approved, adding 1,214,580 shares to the share reserve; total now up to 7,001,185 shares.
Class I director Daniel Baker, Ph.D., re-elected with 18.9M votes for (98.9% of votes cast), 22,995 withheld.
KPMG LLP ratified as independent auditor for FY2025 with 20.8M votes for, 300 against, 2,272 abstain.
Plan also provides annual automatic increase of up to 5% of outstanding shares each January 1 through 2034.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.